148 related articles for article (PubMed ID: 29529882)
1. Response: Atrial impairment in transthyretin cardiac amyloidosis: an early marker of cardiac involvement and a prognostic factor.
Henein MY; Lindqvist P
Amyloid; 2018 Jun; 25(2):136. PubMed ID: 29529882
[No Abstract] [Full Text] [Related]
2. Atrial impairment in transthyretin cardiac amyloidosis: an early marker of cardiac involvement and a prognostic factor.
Di Bella G; Minutoli F
Amyloid; 2018 Jun; 25(2):135. PubMed ID: 29523040
[No Abstract] [Full Text] [Related]
3. A case of transthyretin amyloidosis with myopathy, neuropathy, and cardiomyopathy resulting from an exceedingly rare mutation transthyretin Ala120Ser (c.418G > T, p.Ala140Ser).
Patel K; Tagoe C; Bieri P; Weidenheim K; Tauras JM
Amyloid; 2018 Sep; 25(3):211-212. PubMed ID: 30039724
[No Abstract] [Full Text] [Related]
4. Unmasking Early Wild-Type Transthyretin Amyloidosis Cardiomyopathy in a Patient With Refractory Atrial Fibrillation and Unremarkable Cardiac Imaging.
Varedi D; Kovacsovics T; Downs Kelly E; Abraham J; Cowley J; Barrell K; Revelo MP; Stehlik J; Drakos S; Marrouche N; Wilson B; Swanson EA; Fang J; Nativi-Nicolau J
Circ Heart Fail; 2018 Jul; 11(7):e004812. PubMed ID: 29921704
[No Abstract] [Full Text] [Related]
5. CMR and amyloid cardiomyopathy: are we getting closer to the biology?
Kwong RY; Jerosch-Herold M
JACC Cardiovasc Imaging; 2014 Feb; 7(2):166-8. PubMed ID: 24524743
[No Abstract] [Full Text] [Related]
6. Genetic testing improves identification of transthyretin amyloid (ATTR) subtype in cardiac amyloidosis.
Brown EE; Lee YZJ; Halushka MK; Steenbergen C; Johnson NM; Almansa J; Tedford RJ; Cingolani O; Russell SD; Sharma K; Judge DP
Amyloid; 2017 Jun; 24(2):92-95. PubMed ID: 28494620
[TBL] [Abstract][Full Text] [Related]
7. Molecular Mechanisms of Cardiac Amyloidosis.
Saito Y; Nakamura K; Ito H
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008444
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of light-chain and transthyretin-related categories in cardiac amyloidosis: A systematic review and meta-analysis.
Xin Y; Hu W; Chen X; Hu J; Sun Y; Zhao Y
Hellenic J Cardiol; 2019; 60(6):375-383. PubMed ID: 30742933
[TBL] [Abstract][Full Text] [Related]
9. Effect of doxycycline and ursodeoxycholic acid on transthyretin amyloidosis.
Wixner J; Pilebro B; Lundgren HE; Olsson M; Anan I
Amyloid; 2017 Mar; 24(sup1):78-79. PubMed ID: 28042702
[No Abstract] [Full Text] [Related]
10. Cardiac Involvement in a Patient Cohort With Val30Met Mutation Transthyretin Amyloidosis.
Ripoll-Vera T; Buades J; Cisneros E; Gómez Y; Núñez J; Raya M
Rev Esp Cardiol (Engl Ed); 2019 Jan; 72(1):92-94. PubMed ID: 29223374
[No Abstract] [Full Text] [Related]
11. Familial wild-type transthyretin cardiomyopathy.
Benson MD; Berk JL; Connors LH; Dasgupta NR
Amyloid; 2017 Mar; 24(sup1):91-92. PubMed ID: 28434303
[No Abstract] [Full Text] [Related]
12. Identification of Wild-Type Transthyretin Cardiac Amyloidosis by Quantifying Myocardial Extracellular Volume Using Cardiac Computed Tomography in Atrial Arrhythmias.
Oda S; Kidoh M; Takashio S; Nishi M; Kanazawa H; Nagayama Y; Nakaura T; Tsujita K; Ikeda O
Circ Cardiovasc Imaging; 2020 Jun; 13(6):e010261. PubMed ID: 32438825
[No Abstract] [Full Text] [Related]
13. Recognizing Transthyretin Cardiac Amyloidosis in Patients With Aortic Stenosis: Impact on Prognosis.
Sperry BW; Jones BM; Vranian MN; Hanna M; Jaber WA
JACC Cardiovasc Imaging; 2016 Jul; 9(7):904-906. PubMed ID: 27085437
[No Abstract] [Full Text] [Related]
14. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis.
Quarta CC; Solomon SD; Uraizee I; Kruger J; Longhi S; Ferlito M; Gagliardi C; Milandri A; Rapezzi C; Falk RH
Circulation; 2014 May; 129(18):1840-9. PubMed ID: 24563469
[TBL] [Abstract][Full Text] [Related]
15. Effects of liver transplantation and tafamidis in hereditary transthyretin amyloidosis caused by transthyretin Leu55Pro mutation: a case report.
Kon T; Misumi Y; Nishijima H; Honda M; Suzuki C; Baba M; Inomata Y; Obayashi K; Ando Y; Tomiyama M
Amyloid; 2015; 22(3):203-4. PubMed ID: 26123280
[No Abstract] [Full Text] [Related]
16. Prevalence of Atrial Fibrillation and Thromboembolic Risk in Wild-Type Transthyretin Amyloid Cardiomyopathy.
Bukhari S; Barakat AF; Eisele YS; Nieves R; Jain S; Saba S; Follansbee WP; Brownell A; Soman P
Circulation; 2021 Mar; 143(13):1335-1337. PubMed ID: 33779268
[No Abstract] [Full Text] [Related]
17. Nuclear tracers for transthyretin cardiac amyloidosis: time to bone up?
Ruberg FL; Miller EJ
Circ Cardiovasc Imaging; 2013 Mar; 6(2):162-4. PubMed ID: 23512778
[No Abstract] [Full Text] [Related]
18. Coronary ectasia in amyloid cardiomyopathy and neuropathy due to the transthyretin mutation c.323A>G.
Finsterer J; Stöllberger C; Rauschka H; Gatterer E
Heart Lung; 2018; 47(2):127-129. PubMed ID: 29246775
[TBL] [Abstract][Full Text] [Related]
19. Cardiac transthyretin/leukocyte chemotactic factor (LECT) 2 double amyloidosis in a patient suffering from heart failure.
Greulich S; Mahrholdt H; Casadonte R; Steinmüller-Magin L; Latus J; Blessing F; Kriegsmann J; Bekeredjian R; Gawaz M; Klingel K
Clin Res Cardiol; 2023 Mar; 112(3):444-449. PubMed ID: 35925392
[No Abstract] [Full Text] [Related]
20. Reduced myocardial 123-iodine metaiodobenzylguanidine uptake: a prognostic marker in familial amyloid polyneuropathy.
Coutinho MC; Cortez-Dias N; Cantinho G; Conceição I; Oliveira A; Bordalo e Sá A; Gonçalves S; Almeida AG; de Carvalho M; Diogo AN
Circ Cardiovasc Imaging; 2013 Sep; 6(5):627-36. PubMed ID: 23833285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
